Oncternal Therapeutics Q4 2023 GAAP EPS $(3.110) Misses $(3.070) Estimate, Sales $297.000K Beat $137.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics reported Q4 2023 GAAP EPS of $(3.110), missing the $(3.070) estimate, but their sales of $297K beat the $137.5K estimate, showing significant year-over-year growth.

March 07, 2024 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics missed EPS estimates but significantly beat sales forecasts in Q4 2023, indicating strong revenue growth.
Despite missing EPS estimates, the substantial beat on sales forecasts and the impressive year-over-year sales growth are likely to be viewed positively by investors. The revenue growth indicates that the company is expanding its market presence and improving its financial health, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100